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Background: Experimental vaccines targeting Plasmodium falciparum have had some success in recent years.
These vaccines use attenuated parasites, recombinant sporozoite proteins, or DNA and virus combinations to
induce cell-mediated immune responses and/or antibodies targeting sporozoite surface proteins. To capitalize
on the success of these vaccines and understand the mechanisms by which these vaccines function, it is important to
develop assays that measure correlates of protection in volunteers. The inhibition of liver stage development assay
(ILSDA) tests antibodies for the ability to block sporozoite development in hepatocytes. As such the ILSDA is an excellent
candidate assay to identify correlates of humoral protection, particularly against the liver stage of malaria infection. In
addition, the ILSDA can be used as a tool to evaluate novel sporozoite antigens for future vaccine development.
Historically the ILSDA has suffered from low sporozoite infection rates, absence of standardized reagents, and
the subjectivity associated with the traditional primary outcome measures, which depend on microscopy of
stained hepatocyte cultures. This study worked to significantly improve sporozoite infection rates in hepatocytes,
modify key steps in the assay protocol to reduce experimental variability, and demonstrate the utility of the
ILSDA in testing antibodies targeting the circumsporozoite protein.
Methods: Cryopreserved primary human hepatocytes, Plasmodium falciparum sporozoites, and circumsporozoite
antibodies were used to optimize the ILSDA.
Results: Inoculation of cryopreserved primary human hepatocytes with Plasmodium falciparum sporozoites
improved liver stage development in the ILSDA compared to HCO4 cells. In the ILSDA, circumsporozoite
antibodies suppressed liver stage development in cryopreserved primary human hepatocytes in a
concentration-dependent manner. Antibody-mediated suppression of parasite development in the ILSDA at a
96-hour endpoint was more robust than the 24-hour endpoint.
Conclusions: ILSDA performance is improved by the use of cryopreserved primary human hepatocytes,
expediting interactions between sporozoites and hepatocytes, and extending the assay endpoint.
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Approximately half of the world’s population is at risk of
contracting malaria and there were 660,000 deaths from
malaria in 2010 [1]. Additionally, malaria parasites are
becoming increasingly resistant to anti-malarial drugs
[2], underscoring the need for a vaccine. Malaria infec-
tions start with a blood meal from a malaria-infected
mosquito. The mosquito proboscis introduces sporozo-
ites into the skin where the sporozoites then translocate
to the bloodstream. From the bloodstream the sporozo-
ites travel to the liver sinusoid, move through Kupffer
cells, and eventually invade a hepatocyte to initiate
schizogony. After 7–10 days, several thousand merozo-
ites leave each infected hepatocyte to infect red blood
cells (erythrocytes) and cause symptomatic malaria. Vac-
cine efforts have focused on targeting the asymptomatic
sporozoite and liver (pre-erythrocytic) stages of the dis-
ease as a mechanism to prevent both symptoms and
transmission [3-5].
The leading vaccine candidate, RTS,S, protects from
malaria challenge by inducing antibodies targeting the
major surface protein of the sporozoite (circumsporo-
zoite protein, or CSP) [6]. CSP antibodies most likely
function by blocking sporozoite entry and development
in hepatocytes [7,8]. Attenuated whole sporozoite vac-
cines also demonstrate efficacy by protecting volunteers
in human challenge models and appear to induce pro-
tection through both cell-mediated and humoral im-
mune responses [9-11]. Despite the fact that both of
these experimental vaccine approaches induce antibodies
binding to the parasite, there is no highly sensitive or
specific humoral correlate of protection [11]. Both CSP
ELISA and sporozoite IFA titers show significant corre-
lations, but individuals with low titers following vaccin-
ation are sometimes protected, while individuals with
high titers may remain susceptible.
Functional assays are considered a promising approach
to developing stronger markers of protective immunity.
These assays measure the ability of antibodies to interfere
with normal function, such as inhibition of sporozoite mo-
tility, inhibition of sporozoite invasion (ISI), or inhibition
of liver stage development (ILSDA). However, existing
functional assays have been limited by lack of sensitivity,
standardization, and reproducibility, by the non-specific
inhibition exhibited by negative controls and by the sub-
jectivity associated with relying on microscopy and histo-
logical stains to determine parasite viability [11]. This gap
between promise and performance underscores the need
for improved functional assays that quantitatively and re-
producibly predict in vivo protection.
To strengthen existing functional assays, the Liver
Stage Laboratory at the Naval Medical Research Center
has established an in vitro Plasmodium falciparum liver
stage culture system in cryopreserved primary humanhepatocytes (CPHH) with real-time PCR-based measure-
ment of parasite infection rates. In this study, infection
and development rates in CPHH greatly exceed those
observed in hepatocyte-derived cell lines such as HCO4
cells. The culture system allows performance of multiple
liver stage experiments in the same host genetic back-
ground, improving experimental consistency. Here this
culture system has been adapted for the ILSDA, yielding
improved sensitivity and reliability relative to the classic
ISI, which relies on immortalized hepatocyte lines as the
host cell. As proof of principle, results in this study show
that CSP monoclonal antibodies block liver stage devel-
opment in a concentration-dependent manner.
This study describes the development of a new ILSDA
and identifies requirements for the consistent measure-
ment of antibody-mediated inhibition using CSP anti-
bodies as a test reagent. The study highlights the ILSDA
as a promising candidate to identify humoral correlates
of protection from malaria vaccine trials.
Methods
Overview
The ILSDA is similar to the previously described ISI
[12]. Both assays are designed to identify an activity in
sera that blocks invasion into hepatocytes and subse-
quent development [13]. Hollingdale et al. practiced an
ISI technique, whereby antibodies were introduced to
hepatocyte cultures prior to inoculation of sporozoites
[12]. In this study sporozoites were incubated with anti-
bodies prior to inoculating the hepatocytes with the
sporozoite-antibody mixture. In addition, the assay end-
point was delayed in this study to allow invaded sporozo-
ites to develop and non-invaded sporozoites to senesce.
Traditionally, the ISI read-out is performed a few hours to
one day after sporozoite inoculation of hepatocytes. Al-
though a shortened assay duration is convenient for in-
creasing throughput, it can artificially augment the parasite
load due to the presence of free sporozoite stages that have
not yet washed out of the hepatocyte culture or senesced,
resulting in a false signal. In the ILSDA described here,
antibodies are incubated with sporozoites for 20 minutes at
room temperature to allow an opportunity for test anti-
bodies to bind to sporozoite proteins. The sporozoite-
antibody mixture is then inoculated into a primary human
hepatocyte culture. The culture is washed after three hours
and again after 24 hours post-inoculation of sporozoites.
The culture remains undisturbed for 72 hours after the
second wash before harvesting cells, isolating the total
RNA, and performing quantitative real-time PCR (qRT-
PCR) for Pf 18S rRNA.
Antibodies
Navy falciparum sporozoite antibody 1 (NFS1) was de-
veloped in-house at the Naval Medical Research Center.
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Shock Protein 70 (HSP70) antibody was purchased from
LifeSpan Biosciences, Inc (Seattle, WA).
Plating the hepatocytes
Cryopreserved primary human hepatocytes were pur-
chased from Celsis IVT, Inc. (Baltimore, MD). The cell
plating medium was prepared by adding Torpedo™
Antibiotic Mix containing pen/strep, gentamycin, ami-
kacin, and fungizone to InVitroGRO™ CP Medium
(Celsis IVT, Inc.). Vials of hepatocytes were thawed
and added to the cell medium. Hepatocytes were counted
and 140 k-200 k viable cells were added to each well in
LabTek® chamber slides. After a three-hour incubation
period, the medium was replaced with fresh media and in-
cubated overnight.
The HC04 human liver cell line was obtained from Dr.
Jetsumon Sattabongkot and maintained in culture at
37°C and 5% CO2 in DMEM/F12 medium supple-
mented with 10% FBS and 1% penicillin-streptomycin
solution. HC04 (50 k/well) cells were seeded onto ECL
Cell Attachment Matrix (Millipore, Billerica, MA)
coated 48-well plates or LabTek® slides and incubated
overnight. Twenty-four hours after seeding the cells the
wells of the plates and slides were confluent with cells and
contained approximately 140 k-200 k cells/well.
Plasmodium falciparum sporozoite preparation
Plasmodium falciparum (strain NF54)-infected Anoph-
eles stephensi adult females were anesthetized by soaking
with 70% ethanol followed by washing with DMEM
medium containing anti-bacterial and anti-fungal antibi-
otics (BD Biosciences, 100 units/mL of penicillin, 100
units ug/mL of streptomycin, and 0.25 μg/mL of fungi-
zone) and hepatocyte culture medium. Salivary gland
dissection was performed by: 1 – Placing each mosquito
on a glass slide; 2 – Using a dissecting microscope and
two 27-gauge needles, separating the head from the
thorax; 3 – Separating the two sets of salivary glands
from the head and/or thorax and placing the salivary
glands in hepatocyte culture medium in a microcentri-
fuge tube. The salivary glands were then disrupted by
passing the medium through a 29.5-gauge needle and
syringe. The sporozoites were subsequently counted
using a haemocytometer and diluted in hepatocyte cul-
ture medium to a desired concentration.
Infection of hepatocytes
Sporozoites were introduced into the wells containing
CPHH or HC04 cells and incubated at 37°C for 3 hours
to allow sporozoites to infect hepatocytes. As a positive
control for anti-CSP antibodies, sporozoites were incu-
bated for 20 minutes with NFS1 at various concentra-
tions at room temperature prior inoculation. After thesporozoite inoculation, the Lab-Tek slides were centri-
fuged at 110 × g for 1 minute at room temperature to
expedite sporozoite-hepatocyte interactions. After the
three-hour incubation period, CPHH or HC04 cells were
washed with fresh hepatocyte culture medium to remove
non-invaded sporozoites. For the one-day assay (24 hours),
CPHH were incubated overnight until harvested. For the
ILSDA (96 hours), CPHH or HC04 cells were harvested
on Day 4.
Harvesting the hepatocytes
CPHH or HC04 cells were trypsinized, washed once at
835 × g in phosphate-buffered-saline for 5 minutes, and
kept at −80°C until RNA extraction. To generate a
standard curve for the qRT-PCR, sporozoites were seri-
ally diluted in hepatocyte culture medium, desired
sporozoite numbers were added to hepatocyte mono-
layers, and total host-cell/parasite material collected and
stored at −80°C until RNA extraction.
RNA extraction
The cells were removed from −80°C storage and a Qia-
gen RNeasy Mini Kit protocol was followed to extract
the RNA from the cells. The extracted RNA was ana-
lysed with a NanoDrop spectrophotometer (Thermo
Fisher Scientific) and then stored at either 4°C (for
short-term storage) or −20°C (for long-term storage).
Quantitative real-time PCR (qRT-PCR)
For each experiment RNA from each sample was diluted
to the same concentration, added to PCR reaction plates,
and converted to cDNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster
City, CA). Reaction volumes of 20 μL were used in a
Thermal Cycler (MJ Research Inc., Waltham, MA) set at
the following amplification protocol: 25°C for 10 minutes;
37°C for 120 minutes; 85°C for 5 seconds; hold at 4°C. The
resulting cDNA was used immediately or stored at −20°C.
The following probe and primers were used to detect
parasite 18S ribosomal RNA (rRNA): Taqman® MGB
Probe (Applied Biosystems, Sequence: 5′ – 6FAM -
CAG GTC TGT GAT GTC C - MGBNFQ - 3′);
Sequence Detection Primer 1 (Applied Biosystems, Se-
quence: 5′ - TAA CAC AAG GAA GTT TAA GGC
AAC A - 3′); Sequence Detection Primer 2 (Applied
Biosystems, Sequence: 5′ - CGC GTG CAG CCT AGT
TTA TCT - 3′). A plate document on the 7500 Fast Sys-
tem was set up according to experimental design prior
to each run. To prepare the qRT-PCR reaction plate,
cDNA (diluted to 15–20 ng/mL), probe (250 nM) and
primers (600 nM) were mixed with TaqMan® Fast Univer-
sal PCR Master Mix (Applied Biosystems) to a total vol-
ume of 20 μL per reaction in a MicroAmp Fast Optical
96-Well Reaction Plate (Applied Biosystems) covered with
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then placed in a 7,500 Fast Real-Time PCR System (Ap-
plied Biosystems) to quantify parasite 18S rRNA using the
default thermal cycling conditions: Stage 1 – enzyme
activation: 95°C for 20 seconds; Stage 2 (repeated 40
times) – melting at 95°C for 3 seconds, annealing and
polymerization at 60°C for 30 seconds. Results were
analysed using the Applied Biosystems standard PCR
calculation system once each run was completed. Ex-
perimental samples were compared to the standard
curve generated from host cell and sporozoite mixtures
containing known numbers of sporozoites.
Results
Cryopreserved human hepatocytes support Plasmodium
falciparum liver stage development
Studying the liver stage of P. falciparum malaria requires
a robust and reliable system of in vitro parasite cultiva-
tion. Recent efforts to cultivate P. falciparum liver stage
sporozoites have focused on the hepatocyte-derived cell
line HC04 [14]. However, HC04 cells suffer from a low
P. falciparum sporozoite infection rate [14]. After testing
multiple different cell sources, we found that cryopre-


























Figure 1 Development of P. falciparum in CPHH. A: Representative view
schizonts. B: Pf liver stage schizont developing within a CPHH in vitro. Schi
Biosciences, Inc.) followed by fluorescein-tagged secondary antibodies (green
between qRT-PCR Pf 18s rRNA copy number and counting of HSP70-pos
and linear regression (R2) Fifteen data points from 6 separate experiments usi
using sporozoites mixed with NFS-1 are shown. In all of the samples s
sporozoite inoculation. D: Comparison of sporozoite development at 9
bars represent the standard deviation of the mean.supporting liver stage development, consistent with earl-
ier reports using fresh primary human hepatocytes
(FHH) [15]. Unlike FHH, CPHH can be obtained in
large quantities, allowing for a substantial number of re-
peat experiments while holding host cell genotype con-
stant. We inoculated CPHH purchased from commercial
vendors with dissected P. falciparum sporozoites and
found that CPHH with greater than 80% viability sup-
ported robust liver stage parasite development of HSP70-
staining P. falciparum schizonts (Figure 1A and B).
18S rRNA qRT-PCR provides an objective, quantitative
outcome measure for liver stage burden
Liver stage schizonts are often detected using immuno-
fluorescence analysis of fixed cells (Figure 1A and B).
However, these manual counting processes are subject
to operator error and potential bias. To develop a more
quantitative assessment of liver stage parasite biomass
we measured 18S rRNAs from P. falciparum using qRT-
PCR. Two distinct 18S rRNA genes are expressed during
the P. falciparum lifecycle. It was shown that one 18S
rRNA gene was expressed during asexual, or blood-stage
malaria, while the other 18S rRNA gene was expressed























of one 40X field typically contains several P. falciparum (Pf ) liver
zonts were stained with mAb anti HSP70 (purchased from LifeSpan
). Nuclei were stained with DAPI (blue). Scale bar = 20 μm. C: Correlation
itive liver stage schizonts was determined by plotting a scatter chart
ng sporozoites alone and two data points from two separate experiments
hown on the graph hepatocytes were analysed 96 hours after












































Figure 2 Factors influencing P. falciparum liver stage
development in CPHH. A: Effect of various sporozoite numbers on
infection rate of CPHH. CPHH were inoculated with 25 k, 50 k, 75 k,
100 k and 140 k P. falciparum (Pf ) sporozoites. The liver stage
parasite burden was measured by Pf 18s rRNA qRT-PCR on day 1
(D1) and day 4 (D4). Error bars represent the standard deviation of
the mean. B: Effect of centrifugation on invasion rate of CPHH. CPHH
were inoculated with 25 k Pf sporozoites and harvested after
96 hours. Pf 18s rRNA copy numbers of centrifuged samples were
compared to samples without centrifugation. Error bars represent
the standard deviation of the mean.
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the sexual to the asexual copy [16]. For the studies de-
scribed here a set of primers designed to amplify both
the sexual and asexual 18S rRNA was used.
To assess the extent of correlation between 18S rRNA
copy number and liver stage schizonts we infected 200 K
CPHH with 25 K sporozoites in six separate experiments
with duplicate samples in each experiment. Plasmodium
falciparum 18S rRNA qRT-PCR and HSP70 schizont
staining were performed at 96 hours and compared in
parallel, but in different samples, to avoid degradation of
parasite RNA during fixation. For one of the experi-
ments described here exceptionally high schizont yields
of 300–375 HSP70-staining parasites per well were ob-
served with 14,000-20,000 P. falciparum 18S rRNA
copies per sample. Typically, between 10 and 70 HSP70-
stained schizonts were observed per sample correspond-
ing to 1,000-11,000 P. falciparum 18S rRNA copies. To
suppress parasite development we treated sporozoites
with 5 μg/mL of NFS1 antibodies targeting CSP prior to
hepatocyte inoculation. The NFS1-treated sporozoites
produced no detectable HSP70 stained schizonts and es-
sentially no P. falciparum 18S rRNA signal. All of our
samples were plotted with P. falciparum 18S rRNA levels
on the Y-axis against HSP70 stained schizonts on the X-
axis. A line of best fit was applied to the samples assuming
a linear relationship between P. falciparum 18S rRNA and
HSP70 stained schizonts. The coefficient of correlation
between 18S copy number and HSP70 stained schizont
numbers was between an R2 of 0.8362 and 0.95, indi-
cating a strong correlation between ribosomal RNA
levels and stained schizonts (Figure 1C). Removing the
samples that had exceptionally high parasite yields
(300–375 parasites per well) provided an R2 of 0.764.
Because 18S rRNA qRT-PCR is quantitative, highly
specific, and less susceptible to background effects,
18S rRNA levels using qRT-PCR were used for the re-
mainder of the study.
Cryopreserved primary human hepatocytes provide a
significantly higher infection load compared to HC04 cells
Liver stage infection loads of 200 K CPHH or 200 K
HC04 cells inoculated with 25 K dissected P. falciparum
sporozoites were analysed by 18S rRNA qRT-PCR after
96 hours of development in vitro in 20 replicate experi-
ments. CPHH show a 21-fold increase in parasite 18S
rRNA levels compared to HC04 cells infected with the
same number of sporozoites over the same incubation
period (p = 3 × 10-14) (Figure 1D). This result suggests
that CPHH display a marked improvement in parasite
development compared to HC04 cells. Results presented
here and those of Mazier et al. suggest that primary he-
patocytes, but not hepatocyte-derived cell lines support
robust parasite development [15].Liver stage parasite burden approaches saturation after
sporozoite dose escalation
It is reasonable to speculate that incubating CPHH with
an increasing load of sporozoites might result in a con-
comitant elevation in developed liver stage schizonts. To
test this hypothesis 200 k CPHH were incubated with
25 k, 50 k, 75 k, 100 k, or 140 k P. falciparum sporozo-
ites for 24 (1D) or 96 hours (4D) with media changes.
From these samples parasite burden was assessed by
P. falciparum 18S rRNA qRT-PCR. Plasmodium falcip-
arum 18S rRNA levels from these samples showed a
sporozoite-dependent increase in liver-stage parasite in-
fection load (Figure 2A). These results suggest that in-
creasing the number of sporozoites that are co-cultured
with CPHH generally results in an increase in liver stage
parasites. However, the liver stage parasite load appeared
to reach a plateau in samples that were inoculated with
100 K-140 K sporozoites, suggesting that a saturation
point was reached for liver stage development in sam-
ples that were inoculated with >100 K sporozoites. Per-
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Figure 3 Activity of CSP antibodies in the ILSDA. A: CSP
antibodies demonstrate concentration-dependent inhibition of liver
stage development in CPHH. 25 k P. falciparum (Pf ) sporozoites were
mixed with NFS-1 at six different concentrations (0.0003, 0.0016,
0.008, 0.04, 0.2, or 1.0 μg/mL) and inoculated into CPHH. Hepatocytes
were analysed after 96 hours of sporozoite inoculation. Pf 18s rRNA
copy numbers were measured by qRT-PCR. Each data point
shows the mean of a duplicate sample. B: Effects of NFS-1
(10 μg/mL) on the sporozoites ability to invade (1D = 1 day) and
develop (4D = 4 days) in CPHH. Error bars represent the standard
deviation of the mean.
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of hepatocytes yielded a p = 0.0001 for 25 K sporozoites
compared to 50 K sporozoites, p = 0.18 for 50 K sporozo-
ites compared to 70 K sporozoites, p = 3.54 × 10-6 for 50 K
sporozoites compared to 100 K sporozoites, p = 0.002 for
70 K sporozoites compared to 100 K sporozoites, and
p = 0.48 for 100 K sporozoites compared to 140 K spo-
rozoites. Performing a student t-test (equal variance 2-tails)
between the samples analysed after 4 days of sporozoite in-
oculation of hepatocytes yielded a p = 0.002 for 25 K sporo-
zoites compared to 50 K sporozoites, p = 0.09 for 50 K
sporozoites compared to 70 K sporozoites, p = 0.009 for
50 K sporozoites compared to 100 K sporozoites, p = 0.13
for 70 K sporozoites compared to 100 K sporozoites,
and p = 0.32 for 100 K sporozoites compared to 140 K
sporozoites.
Centrifugation enhances sporozoite invasion and liver
stage development
CPHH display a complete adherence to collagen-coated
slides. As a result the hepatocyte media surface is ap-
proximately 2 millimeters from the surface of the cells.
Sporozoites inoculated into the hepatocyte media are
buoyant and might float in the media for an extended
time period before interacting with the hepatocyte tar-
get, possibly losing infectivity during the process. Previ-
ous results indicate that a brief centrifugation of the
sporozoite-inoculated hepatocytes can expedite interac-
tions between the parasite surface proteins and the he-
patocytes [17]. In three replicate experiments it was
observed that centrifugation after inoculation of 200 K
hepatocytes with 25 K sporozoites increased liver stage
parasite load by ~5.3 fold (p = 3 × 10-4) compared to an
inoculum that was not subjected to centrifugation
(Figure 2B). These results suggest that forcing sporozoite-
hepatocyte interactions by centrifugation significantly ele-
vates the liver stage parasite infection load in vitro.
CSP antibodies suppress liver stage development in a
concentration-dependent manner
Although several studies have shown that anti-CSP or
anti-sporozoite antibodies suppress liver stage develop-
ment in the ISI assay, few studies have demonstrated a
concentration-dependent inhibition of sporozoite invasion
or development [12]. To test the potential for linearity in
the ILSDA, a range of CSP antibody concentrations (n = 2
at each antibody concentration) was tested. Using the
anti-CSP antibody NFS1 targeting the NANP-repeat se-
quences of CSP, we observed a clear concentration-
dependent inhibition of parasite 18S levels in the ILSDA
(Figure 3A). Plasmodium falciparum 18S rRNA levels
were not detectable when sporozoites were incubated with
NFS1 antibodies at a concentration range of 0.04-1 μg/
mL, suggesting that these antibodies have potent anti-sporozoite activity. Diluting the NFS1 antibody beyond a
concentration of 0.04 μg/mL de-repressed liver stage de-
velopment resulting in elevated P. falciparum 18S rRNA
levels. Each five-fold dilution of NFS1 antibody resulted in
an approximate 2-fold elevation in P. falciparum 18S
rRNA levels, suggesting that the inhibitory activity of
NFS1 antibodies was concentration dependent.
Assay endpoint is critical during analysis of liver stage
burden
CSP antibodies are used as positive controls in the ISI
assay and ILSDA. In the ISI, investigators incubate spo-
rozoites or hepatocytes with antibodies, inoculate the
sporozoite-antibody mixture into a hepatocyte culture,
and then assay for invaded sporozoites by immunostain-
ing or qRT-PCR after 1–24 hours. The ILSDA is essen-
tially identical to the ISI except the assay endpoint is
extended from 24 to 96 hours to allow for parasite de-
velopment. This study tested NFS-1 anti-CSP antibodies
for liver stage growth inhibition in both the ISI (24 hour
endpoint) and the ILSDA (96 hour endpoint) (Figure 3B).
Using 1 μg/mL of NFS1 in the ILSDA (96-hour endpoint)
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rRNA levels compared to untreated sporozoite samples
(p = 5.95 × 10-15). In contrast, NFS1 antibodies showed
only a minor reduction (<1.5-fold) in P. falciparum
18S rRNA levels compared to untreated control cul-
tures in the ISI (24-hour endpoint) (p = 0.014). Collect-
ively, these results suggest that allowing liver stage
parasites to mature (96 hours) can reveal the inhibitory
activity of anti-sporozoite sera. Conversely short-term
incubation of sporozoites with hepatocytes in the pres-
ence of CSP antibodies (≤ 24 hours) has only a minor
effect on liver stage parasite burden.
Discussion
Establishing a liver stage infection model in
cryopreserved human primary hepatocytes
Understanding the basic science of the P. falciparum
liver stage has been an area of research interest for de-
cades but has been limited by a lack of a productive and
robust culture system. Here a method for cultivating the
P. falciparum liver stage using cryopreserved human he-
patocytes was characterized. This system provides a
higher infection rate than hepatocyte-derived cell lines.
Additionally, the use of CPHH has a distinct advantage
over FHH in that FHH cells represent a finite and variable
resource. Because each human liver has approximately
1 × 1011 hepatocytes [18,19], a single CPHH donor can
provide a series of repeatable experiments studying the
same host/hepatocyte-parasite interaction. Collectively
our results show that CPHH allow experimental repeat-
ability with higher P. falciparum infection rates compared
to immortalized hepatocyte cell lines.
The gold standard for detection of the P. falciparum
liver stage involves immunostaining for exoerythrocytic
forms with antibodies specific for parasite proteins. Im-
munostaining suffers from the subjective interpretation
of what is and is not a liver stage parasite. Additionally,
immunostaining liver stage parasites is less amenable to
automation, which reduces the throughput of the assay.
In this study we performed a correlation analysis of im-
munostained P. falciparum parasites and 18S rRNA
levels. There was a strong correlation between the num-
ber of immunostained, mature liver stage schizonts and
18S rRNA levels in this study. Importantly, these results
are consistent with those observed by previous studies
[20,21]. Collectively, these results suggest that quantify-
ing P. falciparum 18S rRNA levels can function as a
substitute for counting individual liver stage parasites.
Additionally, assaying parasite development by 18S
rRNA qRT-PCR has the potential advantage of increased
throughput and quantitation over immunostaining tech-
niques. Finally, amplification of P. falciparum 18S rRNA
is unambiguous which facilitates throughput and simpli-
fies our experimental readout.Ways to increase productive infections in CPHH
It is natural to assume that increasing sporozoite num-
bers would influence the number of infected hepatocytes
in vitro. Increasing the number of sporozoites that were
incubated with hepatocytes resulted in an elevation in
P. falciparum 18S rRNA levels. However, P. falciparum
18S rRNA levels began to saturate between 100-140 K
sporozoites in wells seeded with 200 k CPHH. Import-
antly, this result suggests that increasing the sporozo-
ite load will not necessarily result in a concomitant
increase in the number of developing liver stage schiz-
onts in CPHH. We hypothesize that this can be explained
by several possible factors. First, it is reasonable to specu-
late that not all P. falciparum sporozoites dissected from
the salivary gland have the potential to bind, invade, and
develop in hepatocytes. In this scenario only sporozoites
that had achieved a particular developmental profile
would have the potential to establish a productive infec-
tion in a hepatocyte. Second, it is possible that the cell sur-
face architecture of most CPHH cells is not ideal for
sporozoite binding and invasion. For example, during the
processing of donor liver tissue, hepatocyte surface pro-
teins might be lost or depleted resulting in a reduction of
host cell binding receptors for sporozoites. Despite the
fact that we do not observe a 1:1 infection ratio of sporo-
zoites to CPHH, this culture system appears superior to
immortalized cell lines derived from hepatocytes for culti-
vating the liver stage of P. falciparum.
Consistent with previous observations, expediting the
interaction between sporozoites and hepatocytes by cen-
trifugation enhanced parasite development [17]. This re-
sult suggests that hepatocyte entry and/or subsequent
development might be dependent on the proximity of
the sporozoite. In this model sporozoites might benefit
from an initial “dive” into the first hepatocyte until find-
ing a final hepatocyte to initiate development. Sporozo-
ites inoculated into culture might float for hours before
precipitating to the tissue culture well bottom to interact
with a hepatocyte. During this time the sporozoites
could lose invasion and/or developmental potential.
ILSDA as a quantitative assay for antibody suppression of
parasite development
The ISI has been used to demonstrate strong anti-
sporozoite activity in sera from RAS-protected volun-
teers, sera from malaria endemic areas, and monoclonal
antibodies targeting CSP. These past experiments have
focused on characterizing antibodies that show an ex-
ceptional inhibition of sporozoite invasion compared to
non-protected or pre-immune samples [11,12,22,23].
NFS-1 antibodies targeting the CSP NANP repeat se-
quence suppressed P. falciparum development in the
ILSDA in a concentration-dependent manner. Using the
ISI, Hollingdale et al. used CSP monoclonal antibodies
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as 2.5 μg/mL [12]. Using similar CSP-targeting anti-
bodies in the ILSDA a complete inhibition of liver stage
development at concentrations as low as 0.04 μg/mL
was observed. These results suggest that the ILSDA has
the potential to identify the anti-sporozoite activities of
non-CSP antibodies that exhibit lower activity (com-
pared to CSP antibodies) in functional assays.ILSDA versus ISI and the importance of assay endpoint
Experiments employing the ISI and ILSDA have yielded
conflicting results [11]. In this study the ILSDA detected
strong anti-sporozoite activity from CSP antibodies
(>1000-fold inhibition) compared to control antibodies.
The anti-sporozoite activity of CSP antibodies in the
ILSDA and the ISI were compared in parallel. While the
experimental conditions of the ILSDA suggested a >1000-
fold inhibition in parasite development, the ISI showed
less than a 1.5-fold reduction in parasite 18S rRNA levels
between samples treated with CSP antibodies compared
to controls. The ILSDA and the ISI are essentially the
same experiment; in both cases sporozoites are incubated
with antibodies for 20 minutes at room temperature and
introduced to hepatocytes, but are incubated for different
periods, either 24 hours (ISI) or 96 hours (ILSDA). There-
fore, the primary difference between the two assays is the
co-incubation time of antibody-bound-sporozoites and
hepatocytes. The difference in observed activity be-
tween the ISI and ILSDA suggests that: 1. Non-invaded
sporozoites provide a background signal during amplifica-
tion of the P. falciparum 18S rRNA, or 2. Antibodies
bound to sporozoites suppress parasite development after
hepatocyte invasion. Taken together, our results suggest
that the ILSDA has the capacity to distinguish hepatocyte-
invaded and developing parasites from non-invaded spo-
rozoites. Because the ILSDA is more sensitive than the
ISI, it should be considered a more conclusive determin-
ation of humoral anti-parasite activity.Conclusions
This work describes an improved method of cultivating
P. falciparum liver stage parasites, identifies ways to en-
hance hepatocyte infection, and used this novel culture
system to assess functional antibody responses to para-
sites using the ILSDA. Future work will assess the
ILSDA for sensitivity and specificity in predicting pro-
tection against controlled human malaria infection in
humans immunized with candidate malaria vaccines in-
ducing protective humoral immunity.Competing interests
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